Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models

被引:4
作者
De Pablo-Moreno, Juan A. [1 ]
Liras, Antonio [1 ]
Revuelta, Luis [2 ]
机构
[1] Univ Complutense Madrid, Sch Biol, Dept Genet Physiol & Microbiol, Madrid, Spain
[2] Univ Complutense Madrid, Sch Vet Med, Dept Physiol, Madrid, Spain
关键词
factor V; prothrombin time; activated partial thromboplastin time; mouse; measurement standardization; transfusion; pathological models; factor V deficiency; HEMOPHILIA-A; PLASMA; TRANSFUSION; HEMORRHAGE; EVOLUTION; SELECTION;
D O I
10.3389/fvets.2022.846216
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Factor V together with activated factor X forms the prothrombinase complex, which transforms prothrombin into thrombin. The Mus musculus species is characterized by very high levels of this factor and short clotting times, which hinders accurate measurements. For that reason, a detailed characterization of such parameters is indispensable. A method was designed as part of this study to provide an accurate determination and standardization of factor V levels, prothrombin time and activated partial thromboplastin time in Mus musculus. Those parameters were evaluated in a sample of 66 healthy animals using a semi-automated coagulometer and human diagnostic reagents in an attempt to determine the most appropriate time of day for the extractions. A mouse-based protocol was designed, capable of making corrections to the samples at dilutions of 1:100 for factor V and at of 1:3 for prothrombin time. The goal was to smoothen the calibration curves, which often present with steep slopes and narrow measurement ranges between one calibration point and another. It was found that the most stable period for blood sample extraction was that comprised between the first 6 h of light. No clinical differences were observed between the sexes and reference intervals were established for factor V (95.80% +/- 18.14; 25.21 s +/- 1.34), prothrombin time (104.31% +/- 14.52; 16.85 s +/- 1.32) and activated partial thromboplastin time (32.86 s +/- 3.01). The results obtained are applicable to human or veterinary biomedical research, to transfusional medicine or to pathological models for diseases such as factor V deficiency.
引用
收藏
页数:10
相关论文
共 45 条
[41]   Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study [J].
Moussa, Mouhamed Djahoum ;
Soquet, Jerome ;
Lamer, Antoine ;
Labreuche, Julien ;
Gantois, Guillaume ;
Dupont, Annabelle ;
Abou-Arab, Osama ;
Rousse, Natacha ;
Liu, Vincent ;
Brandt, Caroline ;
Foulon, Valentin ;
Leroy, Guillaume ;
Schurtz, Guillaume ;
Jeanpierre, Emmanuel ;
Duhamel, Alain ;
Susen, Sophie ;
Vincentelli, Andre ;
Robin, Emmanuel .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (10)
[42]   Discordant High Activated Partial Thromboplastin Time Relative to Anti-Xa Values in Hospitalized Patients is an Independent Risk Factor for Increased 30-day Mortality [J].
Jin, Jing ;
Gummidipundi, Santosh ;
Hsu, Joe ;
Sharifi, Husham ;
Boothroyd, Derek ;
Krishnan, Anandi ;
Zehnder, James L. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024,
[43]   Modifications in accessibility of membrane glycoproteins, binding of specific ligands and coagulation factor V during the activation of platelets in blood emerging from bleeding time wounds [J].
Escolar, G ;
Lozano, M ;
Díaz-Ricart, M ;
Rao, GHR ;
Ordinas, A ;
White, JG .
AMERICAN JOURNAL OF HEMATOLOGY, 1999, 60 (04) :260-267
[44]   A First Case Report of Autoimmune Acquired Factor V Deficiency After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination at the Time of Initiating Haemodialysis [J].
Tasaki, Ayako ;
Fukuda, Akihiro ;
Kudo, Akiko ;
Nishikawa, Emiko ;
Koumatsu, Nobuchika ;
Wada, Megumi ;
Okita, Jun ;
Maruo, Misaki ;
Uchida, Hiroki ;
Nakata, Takeshi ;
Itani, Kazuhito ;
Shibata, Hirotaka .
NEPHROLOGY, 2025, 30 (02)
[45]   Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial [J].
Aubron, Cecile ;
Chapalain, Xavier ;
Bailey, Michael ;
Board, Jasmin ;
Buhr, Heidi ;
Cartwright, Bruce ;
Dennis, Mark ;
Hodgson, Carol ;
Forrest, Paul ;
Mcilroy, David ;
Murphy, Deirdre ;
Murray, Lynne ;
Pellegrino, Vincent ;
Pilcher, David ;
Sheldrake, Jayne ;
Tran, Huyen ;
Vallance, Shirley ;
Cooper, D. James ;
Mcquilten, Zoe .
CRITICAL CARE EXPLORATIONS, 2023, 5 (11) :E0999